New cancer research could help boost immunotherapy treatments
Scientists have found a way to pull down the protective wall that surrounds tumours, potentially re-exposing them to the killing power of the immune system.
Read More
Author: Anna Smith
Lilly’s atopic dermatitis drug hits endpoints
Both the 4mg and 2mg dosages met the trials’ primary endpoint in BREEZE-AD1 and BREEZE-AD2.
Read More
NICE to work with GW Pharma after Epidiolex rejection
The committee also cited concerns about the economic models provided by the company.
Read More
Positive multiple myeloma results for GSK
Belantamab mafodotin is on track for regulatory submission by the end of 2019.
Read More
FDA Fast Track granted for AZ’ Forxiga
The indication, chronic kidney disease, is a serious, progressive condition defined by decreased kidney function.
Read More- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
- CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
- FDA approves new high dose Spinraza regimen for SMA
